Re:Cognition Health has recently appointed Dustin Reibe as clinical services director.
In his new role, Reibe is responsible for the leadership and development of Re:Cognition Health’s private patient and medicolegal business. This includes developing Re:Cognition’s neurological and neuro-psychiatric specialist services for acquired, traumatic, developmental and neurodegenerative conditions affecting the brain and mind. In addition, Reibe will be leading the introduction of Re:Cognition Health’s new medicinal cannabis and long Covid clinics.
Commenting on the new role, Reibe said: ‘Re:Cognition Health’s vision to change the future of brain and mind health is inspirational and I am thrilled to be in a unique position, at the forefront of innovation in brain and mind services, for the future.
‘Cognitive health is an increasingly significant health priority, due to the UK’s aging demographic and individual lifestyle choice, for a healthy brain and mind, at all ages. My goal is to expand Re:Cognition’s footprint within the UK and position the company to meet future demands. I am looking forward to working with incredible clinicians, partners and the private medical insurers.’
Dr Emer MacSweeney, founder & CEO of Re:Cognition Health, said: ‘We are delighted Dustin Reibe has joined our energetic and forward thinking team. This is an extremely exciting time, worldwide, for new biomarkers and medications for diseases affecting the brain and mind. The rate of change and process in this challenging arena of healthcare has never been more rapid. It is a great time for the company to welcome an individual with Reibe’s commercial healthcare knowledge, operational skills and entrepreneurial experience.’
Carter Schwartz’s head of practice, Linda Stock advised on the appointment.